Acurx Pharmaceuticals Inc (NAS:ACXP)
$ 1.87 -0.01 (-0.53%) Market Cap: 30.38 Mil Enterprise Value: 24.02 Mil PE Ratio: 0 PB Ratio: 8.74 GF Score: 44/100

Q4 2023 Acurx Pharmaceuticals Inc Earnings Call Transcript

Mar 18, 2024 / 12:00PM GMT
Release Date Price: $2.59 (-4.78%)
Operator

Greetings, and welcome to the Acurx Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Earnings Results and Business Update Call. (Operator Instructions) As a reminder, this conference is being recorded.

I would now like to turn the call over to your host, Rob Shawah, Chief Financial Officer for Acurx Pharmaceuticals. Thank you. You may begin.

Robert G. Shawah
Acurx Pharmaceuticals, Inc. - Co-Founder & CFO

Thank you, Melissa. Good morning, and welcome to our call. This morning, we issued a press release providing financial results and company highlights for the fourth quarter and full year 2023, which is available on our website at acurxpharma.com.

Joining me today is David Luci, President and CEO of Acurx; as well as Robert DeLuccia, Executive Chairman. David will give a corporate update and outlook. After that, I'll provide some highlights of the financials from the quarter and year ended December 31, 2023. I'll then turn the call back over to Dave for his closing remarks.

As a reminder, during today's call, we'll be

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot